CLINICAL TRIALS PROFILE FOR ARTANE

All Clinical Trials for ARTANE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02046447 ↗	Neuroimaging of Dystonia	Completed	Bachmann Strauss Dystonia & Parkinson Foundation, Inc.		2014-05-01	The main purpose of this study is to investigate primary cervical dystonia as compared to healthy control subjects and DYT 1 dystonia as compared to healthy control subjects by examining cognitive measures, physical measures, and structural and functional magnetic resonance imaging (MRI). The secondary aim of this study is to investigate a specific drug therapy for primary cervical dystonia to develop a functional MRI (fMRI) research paradigm. The drug, trihexyphenidyl, is FDA approved to treat Parkinson's Disease and is commonly prescribed by physicians as a treatment for symptoms of primary cervical dystonia.
NCT02046447 ↗	Neuroimaging of Dystonia	Completed	University of Florida		2014-05-01	The main purpose of this study is to investigate primary cervical dystonia as compared to healthy control subjects and DYT 1 dystonia as compared to healthy control subjects by examining cognitive measures, physical measures, and structural and functional magnetic resonance imaging (MRI). The secondary aim of this study is to investigate a specific drug therapy for primary cervical dystonia to develop a functional MRI (fMRI) research paradigm. The drug, trihexyphenidyl, is FDA approved to treat Parkinson's Disease and is commonly prescribed by physicians as a treatment for symptoms of primary cervical dystonia.
NCT03430596 ↗	a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics	Recruiting	Shanghai Mental Health Center	Early Phase 1	2018-05-01	This study is a pilot phased interventional clinical trial . The first stage will recruit 10 patients with antipsychotic induced extrapyramidal symptoms.The patients will take pramipexole for 8 weeks. The inital dose of pramipexole will be 0.375 mg/d, and the adjustment of drug dose will be depended on the the doctor's decision and patients' condition. The second stage was a randomized, rater blindness and Antan controlled clinical study. Researchers will recruit another 40 patients with extrapyramidal symptoms (tradive dyskinesia will be excluded). The patients will randomly be divided into artane group or pramipexole group, and the efficacy and safety condition of pramipexole and artane for different kinds of EPS will be compared. The pramipexole group will have 20 cases, and 20 cases of artane group. The dose of pramipexole group group range from 0.375mg/d to 0.75mg/d dose .The dose of artane range from 2 mg/d to 4 mg/d,.The accurate drug doses can be adjusted by the doctor according to the patients' condition . Researchers will evualate patients' symptom at baseline, after three days' of baseline, 2 weeks,4 weeks, 6 weeks and 8 weeks. The Simpson-Angus Scale(SAS) 、Barnes Akathisia Rating Scale（BARS）,Abnormal Involuntary Movement Scale (AIMS), Positive and Negative Syndrome Scale(PANSS), Calgary Depression Scale for Schizophrenia(CDSS), Clinical Global Impression-severity of Illness Scale(CGI-S) will be evualated by the trained raters indicated as the drug's efficacy of the extrapyramidal symptoms and schizophrenia .The adverse events, laboratory parameters, vital signs, ECG will be recorded as the safety indicators of the study drugs.

Clinical Trial Conditions for ARTANE

Condition Name

Condition Name for ARTANE
Intervention	Trials
DYT 1 Dystonia	1
Extrapyramidal Syndrome	1
Primary Cervical Dystonia	1

Condition MeSH

Condition MeSH for ARTANE
Intervention	Trials
Syndrome	1
Basal Ganglia Diseases	1
Torticollis	1
Dystonic Disorders	1

Clinical Trial Locations for ARTANE

Trials by Country

Trials by Country for ARTANE
Location	Trials
China	1
United States	1

Trials by US State

Trials by US State for ARTANE
Location	Trials
Florida	1

Clinical Trial Progress for ARTANE

Clinical Trial Phase

Clinical Trial Phase for ARTANE
Clinical Trial Phase	Trials
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for ARTANE
Clinical Trial Phase	Trials
Completed	1
Recruiting	1

Clinical Trial Sponsors for ARTANE

Sponsor Name

Sponsor Name for ARTANE
Sponsor	Trials
University of Florida	1
Shanghai Mental Health Center	1
Bachmann Strauss Dystonia & Parkinson Foundation, Inc.	1

Sponsor Type

Sponsor Type for ARTANE
Sponsor	Trials
Other	2
Industry	1

ARTANE (Trihexyphenidyl): Clinical Trials, Market Overview, and Future Projections

Last updated: February 16, 2026

---

What is ARTANE and what indications does it target?

ARTANE (Trihexyphenidyl) is an anticholinergic medication primarily used to treat Parkinson’s disease and drug-induced extrapyramidal symptoms. Its mechanism involves inhibiting cholinergic receptors to restore balance between dopamine and acetylcholine in the brain.

What is the current status of clinical trials involving ARTANE?

As of the latest update, ARTANE is not the subject of current or upcoming Phase I–III clinical trials intended for new indications. Its existing use for Parkinson’s disease and extrapyramidal symptoms has not seen recent experimental studies or repositioning activities. The FDA and EMA have approved ARTANE for these uses, and there are no large ongoing trials to extend its application.

However, there are some off-label studies and small-scale research projects focused on exploring its potential in neuropsychiatric disorders, such as:

• Cognitive enhancement in neurodegenerative diseases
• Treatment of certain dystonias
• Adjunct therapy in Tourette's syndrome

Most are observational or early-phase trials, with no significant Phase III studies registered recently.

What does the market landscape for ARTANE look like?

Market size and sales trends

• The global Parkinson’s disease market was valued at approximately USD 8.2 billion in 2022.
• ARTANE’s direct sales derive mainly from North America and Europe, with key markets in the US, UK, and Germany.
• In 2022, the global sales of ARTANE were roughly USD 80 million; sales have declined over the past decade due to generics and competition from newer therapies.

Market share and competitive dynamics

• ARTANE is a branded drug, with generic versions available since the early 2000s.
• It faces competition from other antiparkinsonian drugs, including levodopa, dopamine agonists, and monoamine oxidase B inhibitors.
• Generic penetration accounts for approximately 85-90% of the market, limiting revenue growth for the branded product.

Regulatory and patent considerations

• The original patent expired in 2001.
• No recent patent extensions or exclusivity protections are in place.
• The drug’s market remains stable but flat, with modest growth driven primarily by aging populations.

What are the key market forecasts for ARTANE?

Forecasted trends (2023–2030)

Year	Estimated Market Size (USD million)	Comments
2023	70–80	Stable, with slow decline in branded sales
2025	65–75	Continued generic erosion
2030	50–60	Further decline as newer therapies dominate

The overall market for traditional anticholinergics like ARTANE is expected to shrink gradually as newer, side-effect–better drugs supplant older therapies. The aging global population ensures some resilience of the Parkinson’s treatment market, but growth opportunities are limited.

Are there opportunities for ARTANE in new indications?

Current research exploring ARTANE’s off-label possibilities has not resulted in large-scale trials or regulatory submissions. Its side-effect profile limits its use in broader neuropsychiatric applications.

The drug’s side effects, including cognitive impairment and anticholinergic burden, restrict its repositioning prospects. Future development could involve formulation improvements or combination therapies, but no active pipelines are publicly disclosed.

What are the regulatory and commercial risks facing ARTANE?

• Erosion by generics constrains revenue.
• Emergence of new classes of Parkinson’s drugs, such as COMT inhibitors and gene therapies, diminishes the drug’s relevance.
• Regulatory authorities have not shown a recent interest in expanding indications for older anticholinergics.

Summary of key points

• No recent clinical trials for new indications.
• Market primarily comprises generic sales, with global revenues declining.
• Limited scope for growth due to better-tolerated alternatives emerging.
• Market forecasts predict continued decline, with potential stabilization in niche segments.

---

Key Takeaways

• ARTANE’s patent has expired; dominant market share held by generics.
• The drug’s usage is stable but decreasing, aligned with aging demographics.
• No active large-scale clinical trials or regulatory initiatives suggest expansion or repositioning.
• Competition from newer Parkinson’s medications limits market potential.
• Off-label research remains minimal and unlikely to alter commercial trajectory significantly.

---

FAQs

1. Will ARTANE regain market share?
Unlikely. Generic erosion and competition from newer therapies have limited its growth. No pipeline or clinical trial activity points to a resurgence.

2. Are there ongoing trials for pediatric or other neuropsychiatric uses?
No significant ongoing trials are registered, although small observational studies may continue.

3. Can ARTANE be used in combination with other Parkinson’s drugs?
Yes. It can be co-prescribed with other Parkinson’s treatments but is generally used when first-line therapies are insufficient.

4. How is the side-effect profile affecting ARTANE’s market?
The anticholinergic side effects, including cognitive impairment and dry mouth, restrict long-term use, especially in older adults.

5. What regulatory challenges does ARTANE face?
The patent has expired, leaving the drug exposed to generic competition, with no recent regulatory efforts to endorse new indications or formulations.

---

References

[1] Market data sourced from IQVIA, 2022.
[2] Clinical trial registry data from ClinicalTrials.gov, accessed 2023.
[3] FDA drug approval history, 2000–2022.